Montelukast reduces grey matter abnormalities and functional deficits in a mouse model of inflammation-induced encephalopathy of prematurity

Encephalopathy of prematurity (EoP) affects approximately 30% of infants born < 32 weeks gestation and is highly associated with inflammation in the foetus. Here we evaluated the efficacy of montelukast, a cysteinyl leukotriene receptor antagonist widely used to treat asthma in children, to ameli...

Descripción completa

Detalles Bibliográficos
Autores principales: Yates, Abi G., Kislitsyna, Elena, Alfonso Martin, Carla, Zhang, Jiaying, Sewell, Amy L., Goikolea-Vives, Ane, Cai, Valerie, Alkhader, Lama F., Skaland, Aleksander, Hammond, Basil, Dimitrova, Ralica, Batalle, Dafnis, Fernandes, Cathy, Edwards, A. David, Gressens, Pierre, Thornton, Claire, Stolp, Helen B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617353/
https://www.ncbi.nlm.nih.gov/pubmed/36309753
http://dx.doi.org/10.1186/s12974-022-02625-5

Ejemplares similares

Ejemplares similares